Spatial Transcriptional Landscape of Human Heart Failure
Ontology highlight
ABSTRACT:
PROVIDER: PRJNA1132899 | ENA |
REPOSITORIES: ENA
Dataset's files
| Action | DRS | |||
|---|---|---|---|---|
| Other | ||||
| SRR29732100_1.fastq.gz | Fastqsanger.gz | |||
| SRR29732100_2.fastq.gz | Fastqsanger.gz | |||
| SRR29732200_1.fastq.gz | Fastqsanger.gz | |||
| SRR29732200_2.fastq.gz | Fastqsanger.gz |
Items per page: 5 1 - 5 of 1417 |
Similar Datasets
Project description:Heart failure (HF) poses a major clinical challenge with diverse underlying causes. Despite advances, the intricate molecular alterations specific to distinct cell types and histological patterns during HF progression remain inadequately characterized. Using the GeoMx whole human transcriptome digital spatial profiler, we discerned gene expression dynamics in failing human hearts, integrating cell type, clinical, and histological nuances. We demonstrated the cellular composition of the left ventricle myocardium and validated the GeoMx platform's compartmentalization efficiency, showing high accuracy for cardiomyocytes but limitations for endothelial cells and fibroblasts. Gene regulation in HF was influenced by cellular context, with contrasting patterns across cell types. Differentially expressed genes, such as UCHL1, IGFBP2, CCL14, ACKR1, and PLVAP, were linked to specific histologic features like degeneration and fibrosis. Multiplex immunohistochemistry confirmed the co-localization of PLVAP and ACKR1 in endothelial cells, correlating with fibrosis severity. Furthermore, our data highlight pronounced inflammatory responses in end-stage HF. Integrative analysis, combining histological and clinical perspectives, spotlighted CRIP3, PFKFB2, and TAX1BP3 as potential contributors to HF progression. Our findings underscore the pivotal role of cell enriched and histology-specific transcriptome mapping in understanding the complex pathophysiological landscape of failing hearts, unveiling potential therapeutic targets and molecular insights.
2025-05-08 | GSE271676 | GEO
Project description:Heart failure represents a major cause of morbidity and mortality worldwide. Single cell transcriptomics have revolutionized our understanding of cell composition and associated gene expression across human tissues. Through integrated analysis of single cell and single nucleus RNA sequencing data generated from 45 individuals, we define the cell composition of the healthy and failing human heart. We identify cell specific transcriptional signatures of heart failure and reveal the emergence of disease associated cell states. Intriguingly, cardiomyocytes converge towards a common disease associated cell state, while fibroblasts and myeloid cells undergo dramatic diversification. Endothelial cells and pericytes display global transcriptional shifts without changes in cell complexity. Collectively, our findings provide a comprehensive analysis of the cellular and transcriptomic landscape of human heart failure, identify cell type specific transcriptional programs and states associated with disease, and establish a valuable resource for the investigation of human heart failure.
2022-01-28 | GSE183852 | GEO
Project description:Heart failure is driven by the interplay between master regulatory transcription factors and dynamic alterations in chromatin structure. Coordinate activation of developmental, inflammatory, fibrotic and growth regulators underlies the hallmark phenotypes of pathologic cardiac hypertrophy and contractile failure. While transactivation in this context is known to be associated with recruitment of histone acetyl-transferase enzymes and local chromatin hyperacetylation, the role of epigenetic reader proteins in cardiac biology is unknown. We therefore undertook a first study of acetyl-lysine reader proteins, or bromodomains, in heart failure. Using a chemical genetic approach, we establish a central role for BET-family bromodomain proteins in gene control during the evolution of heart failure. BET inhibition suppresses cardiomyocyte hypertrophy in a cell-autonomous manner, confirmed by RNA interference in vitro. Following both pressure overload and neurohormonal stimulation, BET inhibition potently attenuates pathologic cardiac remodeling in vivo. Integrative transcriptional and epigenomic analyses reveal that BET proteins function mechanistically as pause-release factors critical to activation of canonical master regulators and effectors that are central to heart failure pathogenesis. Specifically, BET bromodomain inhibition in mice abrogates pathology-associated pause release and transcriptional elongation, thereby preventing activation of cardiac transcriptional pathways relevant to the gene expression profile of failing human hearts. This study implicates epigenetic readers in cardiac biology and identifies BET co-activator proteins as therapeutic targets in heart failure. ChIP-Seq of mouse heart tissues from mice induced with heart failure and treated with JQ1 BET bromodomain inhibitor
2013-08-06 | E-GEOD-46668 | biostudies-arrayexpress
Project description:Heart Failure Network: EntrestoTM In Advanced Heart Failure (HFN-LIFE-BioLINCC)
| PRJNA1290831 | ENA
Project description:Heart Failure Network: EntrestoTM In Advanced Heart Failure (HFN-LIFE-BioLINCC)
| PRJNA1290830 | ENA
Project description:Spatial transcriptomics links gene expression with tissue morphology, however, current tools often prioritize genomic analysis, lacking integrated image interpretation. To address this, we present Thor, a comprehensive platform for cell-level analysis of spatial transcriptomics and histological images. Thor employs an anti-shrinking Markov diffusion method to infer single-cell spatial transcriptome from spot-level data, effectively combining gene expression and cell morphology. The platform includes 10 modular tools for genomic and image-based analysis, and is paired with Mjolnir, a web-based interface for interactive exploration of gigapixel images. Thor is validated on simulated data and multiple spatial platforms (ISH, MERFISH, Xenium, Stereo-seq). Thor identifies regenerative signatures in heart failure, unbiasedly screens breast cancer hallmarks, resolves fine layers in mouse olfactory bulb, and annotates fibrotic heart tissue. In high-resolution Visium HD data, it enhances spatial gene patterns aligned with histology. By bridging transcriptomic and histological analysis, Thor enables holistic tissue interpretation in spatial biology.
2025-07-11 | GSE300585 | GEO
Project description:Heart failure is driven by the interplay between master regulatory transcription factors and dynamic alterations in chromatin structure. Coordinate activation of developmental, inflammatory, fibrotic and growth regulators underlies the hallmark phenotypes of pathologic cardiac hypertrophy and contractile failure. While transactivation in this context is known to be associated with recruitment of histone acetyl-transferase enzymes and local chromatin hyperacetylation, the role of epigenetic reader proteins in cardiac biology is unknown. We therefore undertook a first study of acetyl-lysine reader proteins, or bromodomains, in heart failure. Using a chemical genetic approach, we establish a central role for BET-family bromodomain proteins in gene control during the evolution of heart failure. BET inhibition suppresses cardiomyocyte hypertrophy in a cell-autonomous manner, confirmed by RNA interference in vitro. Following both pressure overload and neurohormonal stimulation, BET inhibition potently attenuates pathologic cardiac remodeling in vivo. Integrative transcriptional and epigenomic analyses reveal that BET proteins function mechanistically as pause-release factors critical to activation of canonical master regulators and effectors that are central to heart failure pathogenesis. Specifically, BET bromodomain inhibition in mice abrogates pathology-associated pause release and transcriptional elongation, thereby preventing activation of cardiac transcriptional pathways relevant to the gene expression profile of failing human hearts. This study implicates epigenetic readers in cardiac biology and identifies BET co-activator proteins as therapeutic targets in heart failure.
2013-08-06 | GSE46668 | GEO
Project description:Cardiac hypertrophy is a pathological feature of heart failure, and dysregulation of protein turnover and autophagy has been implicated in its progression. Speckle-type POZ protein (SPOP), a substrate adaptor for the Cullin3-RING E3 ubiquitin ligase complex, plays an emerging role in protein homeostasis and transcriptional regulation. This study investigates the function of SPOP in cardiac hypertrophy and heart failure. RNA sequencing was performed to examine transcriptional changes in mouse hearts with cardiac-specific overexpression of SPOP, revealing differential expression of genes involved in autophagy, mitochondrial metabolism, and cardiac remodeling. These data provide new insights into the transcriptional landscape regulated by SPOP in the hypertrophic heart.
2025-08-26 | GSE304791 | GEO
Project description:Despite some success of pharmacotherapies targeting primarily neurohormonal dysregulation, heart failure is a growing global pandemic with increasing burden. Treatments that improve the disease by reversing heart failure at the cardiomyocyte level are lacking. MicroRNAs (miRNA) are transcriptional regulators of gene expression, acting through complex biological networks, and playing thereby essential roles in disease progression. Adverse structural remodelling of the left ventricle due to myocardial infarction (MI) is a common pathological feature leading to heart failure. We previously demonstrated increased cardiomyocyte expression of the miR-212/132 family during pathological cardiac conditions. Transgenic mice overexpressing the miR-212/132 cluster (miR-212/132-TG) develop pathological cardiac remodelling and die prematurely from progressive HF. Using both knockout and antisense strategies, we have shown miR-132 to be both necessary and sufficient to drive the pathological growth of cardiomyocytes in a murine model of left ventricular pressure overload. Based on the findings, we proposed that miR-132 may serve as a therapeutic target in heart failure therapy. Here we provide novel mechanistic insight and translational evidence for the therapeutic efficacy in small and large animal models (n=135) of heart failure. We demonstrate strong PK/PD relationship, dose-dependent efficacy and high clinical potential of a novel optimized synthetic locked nucleic acid phosphorothioate backbone antisense oligonucleotide inhibitor of miR-132 (antimiR-132) as a next-generation heart failure therapeutic.
2020-01-09 | PXD015337 | Pride